Author Search Results :: UTM Library Massive Scholar Tracking

1

Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches by Walter Hanel, Alex F. Herrera, Narendranath Epperla

Published 2022-12-01

Get full text

Article

2

P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA by Philippe Armand, Pier Luigi Zinzani, John Timmerman, Nathalie Johnson, David Lavie, Kannan Thiagarajan, Brian Topp, Pallavi Pillai, Alex F. Herrera

Published 2023-08-01

Get full text

Article

3

$P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma$

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma by Swetha Kambhampati, Matthew Mei, Lu Chen, Sandrine Puvurel, Robert Chen, Leslie Popplewell, Liana Nikolaenko, Lacolle Peters, Saro Armenian, Larry Kwak, Steven T. Rosen, Stephen Forman, Alex F. Herrera

Published 2022-10-01

Get full text

Article

4

$P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma$

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma by Matthew Mei, Joycelynne Palmer, Kami Maddocks, Peter Martin, Ni-Chun Tsai, Eileen Smith, Leslie Popplewell, Saro Armenian, Geoffrey Shouse, Robert Chen, Larry Kwak, Steven T. Rosen, Stephen Forman, David Bond, Alex F. Herrera

Published 2022-10-01

Get full text

Article

5

P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER... by John Timmerman, David Lavie, Nathalie Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera

Published 2023-08-01

Get full text

Article

6

$T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment$

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to An... by John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Hong Zhang, Pallavi Pillai, Akash Nahar, Alex F. Herrera

Published 2022-10-01

Get full text

Article

7

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN... by Nathalie Johnson, David Lavie, Peter Borchmann, Gareth Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman

Published 2023-08-01

Get full text

Article

8

$P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma$

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma... by Peter Borchmann, Nathalie A. Johnson, David Lavie, Gareth Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, John Palcza, Pallavi Pillai, Akash Nahar, John Timmerman

Published 2022-10-01

Get full text

Article

9

S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT by Nausheen Ahmed, Swetha Kambhampati, Mehdi Hamadani, Natalie Grover, Mazyar Shadman, Frederick Locke, James Gerson, Matthew J. Frank, L. Elizabeth Budde, Michael Wang, Zhen-Huan Hu, Ana Nunes, David Dalton, Ioana Kloos, Daniel Lee, Hairong Xu, Marcelo Pasquini, Alex F. Herrera

Published 2023-08-01

Get full text

Article

10

$Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma$

Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma by Pallawi Torka, Swetha Kambhampati, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja, D. Lynne Smith, Alex F. Herrera, Stephen E. F. Spurgeon, Byung Park, Lionel D. Lewis, Francisco Hernandez-Ilizaliturri, Zheng Xia, Alexey V. Danilov

Published 2023-01-01

Get full text

Article

11

$P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data$